Drugs / ANG1005
ANG1005
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00539344 | Oct 2007 → Mar 2010 | malignant glioma | Angiochem Inc | Completed | No outcome recorded |
| Phase 1 | NCT00539383 | Oct 2007 → Mar 2010 | neoplasm | Angiochem Inc | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02048059 | Apr 2014 → Mar 2016 | breast cancer, metastatic malignant neoplasm in the brain | Angiochem Inc | Completed | No outcome recorded |
| Phase 2 | NCT01967810 | Oct 2013 → Feb 2016 | brain cancer, glioblastoma | Angiochem Inc | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03613181 | Dec 2023 → Dec 2024 | Her2-receptor negative breast cancer, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain, neoplastic meningitis | Angiochem Inc | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02755987 | — | anaplastic astrocytoma, anaplastic oligodendroglioma, breast cancer, neoplastic meningitis | Angiochem Inc | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2020-03-05 | Beijing Shenogen Biomedical Co., Ltd | Results SNG1005 II期临床结果发表在《临床癌症研究》显示治疗乳腺癌脑软膜转移癌和复发性乳腺癌脑实质转移癌的活性 shenogen.com ↗
SNG1005的安全性与普通紫杉醇类似且无严重全身过敏反应。 |
| 2019-05-31 | Beijing Shenogen Biomedical Co., Ltd | Regulatory SNG1005获得CDE批准开展治疗既往全脑放疗后脑实质进展的HER2阴性乳腺癌脑转移患者的临床试验 shenogen.com ↗
2019 年 5 月 29 日，国家药品监督管理局药品审评中心已批准北京盛诺基医药科技有限公司在中国开展“一项化药 1 类新药注射用 SNG1005 治疗既往全脑放疗后脑实质进展的 HER2 阴性乳腺癌脑转移患者的多中心、随机对照、开放标签临床试验”（受理号： JXHL1900058 ） |
| 2018-08-06 | Angiochem Inc | Regulatory Angiochem Announces Special Protocol Assessment (SPA) with US Food and Drug Administration (FDA) angiochem.com ↗
Angiochem Inc. (“Angiochem”) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis plan for a Phase 3 clinical trial for ANG1005. |
| 2016-10-17 | Angiochem Inc | Results Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain Metastases angiochem.com ↗
In this report of the multi-center, open label Phase II trial ANG1005-CLN-04, ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases. |
| 2016-06-06 | Angiochem Inc | Results Angiochem’s ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II Trial angiochem.com ↗
Their lead compound, ANG1005, demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases (BCBM patients) and leptomeningeal carcinomatosis (LC). |
| 2014-05-30 | Angiochem Inc | Regulatory Angiochem’s ANG1005 Received Orphan Drug Designation from FDA for the Treatment of Glioblastoma multiform angiochem.com ↗
We are pleased that the FDA supports our applications for both fast track and orphan drug designation for ANG1005 for the treatment of glioblastoma multiforme. |
| 2013-10-21 | Angiochem Inc | Results PHASE 2 CLINICAL DATA FOR ANGIOCHEM’S LEAD DRUG CANDIDATE, ANG1005, IN BREAST CANCER PATIENTS WITH BRAIN METASTASES REVEALED angiochem.com ↗
These data, which include the complete intent-to-treat (ITT) analysis, demonstrated promising signs of anti-tumor activity, and support the company’s decision to advance the ANG1005 clinical development program. |
| 2012-12-03 | Geron Corporation | Results Geron Discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres geron.com ↗
This analysis showed that there were no confirmed intra-cranial responses, as determined by an Independent Review Facility, among the first 30 evaluable patients in the trial. |
| 2011-11-15 | Angiochem Inc | Results GERON PRESENTS FINAL PHASE 1 CLINICAL DATA ON GRN1005 AT AACR-NCI-EORTC angiochem.com ↗
The Phase 1 data showed that GRN1005 can penetrate brain tissue and brain tumors in patients, and is well tolerated, with encouraging evidence of anti-tumor activity against brain metastases. |
| 2011-11-15 | Geron Corporation | Results Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC geron.com ↗
The Phase 1 data showed that GRN1005 can penetrate brain tissue and brain tumors in patients, and is well tolerated, with encouraging evidence of anti-tumor activity against brain metastases. |
| 2010-04-20 | Angiochem Inc | Results Angiochem presents data further demonstrating the role of LRP-1 in cancer angiochem.com ↗
These preclinical data demonstrated effective transport of ANG1005 into glioblastoma cells as well as in the transcytosis of ANG1005 at the blood BBB through the LRP-1. |
| 2009-10-18 | Angiochem Inc | Results Angiochem’s ANG1005 demonstrates safety and efficacy in Phase 1/2 brain cancer studies angiochem.com ↗
In the recently completed Phase 1/2 brain metastases clinical trial, greater than 70% of patients receiving therapeutic doses experienced disease control (stable disease or better) with more than half of them showing clear reduction in tumor size. |
| 2009-04-21 | Angiochem Inc | Results New Positive Clinical Data on ANG1005 for Brain Cancers at AACR angiochem.com ↗
The data demonstrated that ANG1005 has potential efficacy as evidenced by tumor regression and the halting of tumor progression; has a favorable safety and tolerability profile; and has the ability to cross the blood-brain barrier to effectively deliver active therapeutic concentrations. |
| 2009-03-19 | Angiochem Inc | Results AngioChem's ANG1005 Shows Promise In theTreatment of Brain Cancers. angiochem.com ↗
The data demonstrated that ANG1005 has a favorable safety and tolerability profile, as evidenced by laboratory and neurocognitive data, and does not show evidence of eliciting an immune response. |
| 2008-10-22 | Angiochem Inc | Results ANG1005 Demonstrates Preliminary Clinical Safety and Tolerability in Brain Cancer Patients. angiochem.com ↗
AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, announced today that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date. |
| 2008-07-10 | Angiochem Inc | Results AngioChem announces two new peer-reviewed publications. angiochem.com ↗
Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. |
All press releases naming this drug 22 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANG1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03613181 ↗ |
| Known as | Paclitaxel trevatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089636 ↗ |
| Known as | Paclitaxel trevatide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089636 ↗ |
| Modality | Peptide | “GRN1005 is a peptide-drug conjugate” PMID 23349317 ↗ Jan 2013 |
| Route | Intravenous | “ANG1005 will be given by IV infusion once every 21 days” NCT00539344 ↗ |
| Target | LRP1 | “by targeting the low-density lipoprotein receptor-related protein-1” PMID 23349317 ↗ Jan 2013 |